Development and Validation of a UHPLC–MS/MS Method for Quantitation of Almonertinib in Rat Plasma: Application to an in vivo Interaction Study Between Paxlovid and Almonertinib

Almonertinib was approved for the first-line treatment of advanced NSCLC patients with EGFR-TKI-sensitive genetic mutations by National Medical Products Administration (NMPA) in 2021.The purpose of this study was to establish and validate a fast, accurate, stable and facile ultra-performance liquid...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Peng-fei, Bao, Su-su, Gao, Nan-yong, Shao, Chuan-feng, Xie, Wei-fei, Wu, Xue-meng, Zhao, Le-ping, Xiao, Zhong-xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355496/
https://www.ncbi.nlm.nih.gov/pubmed/35935882
http://dx.doi.org/10.3389/fphar.2022.960311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355496/
https://www.ncbi.nlm.nih.gov/pubmed/35935882
http://dx.doi.org/10.3389/fphar.2022.960311

Ejemplares similares